Skip to main
AXSM
AXSM logo

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. shows a strong financial outlook, highlighted by a significant increase in gross revenue, which grew from $77.4K in 4Q23 to $194K in 2Q25, primarily attributed to improved coverage and an expanded prescriber base. The company's sales infrastructure has been successfully established, featuring 300 dedicated sales representatives and coverage that reaches 83% of all lives and 73% of commercial lives, fostering sustained revenue growth. Furthermore, the increase in new prescriptions (NRx) and total prescriptions (TRx), with NRx growing by 19% quarter-over-quarter in 2Q25, indicates strong patient retention and growing market adoption, reinforcing Axsome's position in the CNS therapy market.

Bears say

Axsome Therapeutics Inc has reported significant operating losses since its inception, indicating ongoing financial struggles that may impact future growth and investor confidence. Despite notable clinical results with AXS-12—demonstrating a 50% reduction in mean cataplexy attacks—this success may be overshadowed by the broader challenges faced by adults suffering from CNS disorders, including lower employment stability and reduced earnings. The company's reliance on developing therapies for CNS disorders with limited treatment options raises concerns about its financial sustainability and market viability as it continues to navigate operational deficits.

Axsome Therapeutics (AXSM) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 16 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.